Journal article
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Abstract
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction. Spontaneous major bleeding and bleeding associated with urgent invasive procedures are concerns with ticagrelor, as with other antiplatelet drugs. The antiplatelet effects of ticagrelor cannot be reversed with platelet transfusion. A rapid-acting …
Authors
Bhatt DL; Pollack CV; Weitz JI; Jennings LK; Xu S; Arnold SE; Umstead BR; Mays MC; Lee JS
Journal
New England Journal of Medicine, Vol. 380, No. 19, pp. 1825–1833
Publisher
Massachusetts Medical Society
Publication Date
May 9, 2019
DOI
10.1056/nejmoa1901778
ISSN
0028-4793